The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality of life instruments: A systematic review

Vyas, Jui ORCID: https://orcid.org/0000-0003-2839-2651, Johns, Jeffrey ORCID: https://orcid.org/0000-0002-1628-4306, Abdelrazik, Yasmina, Ali, Faraz ORCID: https://orcid.org/0000-0002-4184-2023, Ingram, John ORCID: https://orcid.org/0000-0002-5257-1142, Salek, Sam ORCID: https://orcid.org/0000-0002-4612-5699 and Finlay, Andrew ORCID: https://orcid.org/0000-0003-2143-1646 2024. The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality of life instruments: A systematic review. Journal of the European Academy of Dermatology and Venereology 10.1111/jdv.20321

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (526kB) | Preview

Abstract

Background. The validation of psychometric measures requires use of other established and standardised validated measures. The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure the burden of skin diseases and assess effectiveness of interventions based on patients’ perspective. Objectives. The objective of this study was to systematically analyse peer-reviewed publications describing use of the DLQI in validation of other patient reported outcome (PRO) and quality of life (QoL) measures. Methods. Seven databases were searched for papers published between January 1994 and December 2022 for articles containing data using DLQI in the validation of other PRO/QoL measures. The methodology followed PRISMA guidelines. The protocol was prospectively registered on PROSPERO. Results. Of 1,717 screened publications, 122 articles including 30,727 patients from 34 different countries with 41 diseases met the inclusion criteria. The DLQI was used in validation of 101 measures: 80 dermatology-specific QoL measures, mostly disease-specific, and 21 generic measures. Of these studies, 47 were cross-cultural adaptations, 116 single arm, 100 were cross-sectional, 18 longitudinal, and 6 randomised placebo controlled. DLQI was used for 14 known group, and correlation for 10 construct, 101 convergent, 10 concurrent, 10 divergent/discriminant and 3 criterion validity tests using Mann-Whitney (2), Spearman's (80), Pearson's correlation (26) and Student's t-test (1). The DLQI was used in responsiveness analysis in 13 studies. Conclusions. This review identified widespread use of the DLQI in validation of other dermatology PRO/QoL measures and confirms the central role that the DLQI plays as a benchmark in instrument development and validation across dermatology and beyond. The use of the DLQI by so many developers of other instruments has provided a common standard for comparability.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RL Dermatology
Uncontrolled Keywords:	validation, psychometric, outcome measurement, quality of life
Publisher:	Wiley
ISSN:	1064-7554
Date of First Compliant Deposit:	16 September 2024
Date of Acceptance:	20 August 2024
Last Modified:	02 Oct 2024 16:30
URI:	https://orca.cardiff.ac.uk/id/eprint/171948

Actions (repository staff only)

Edit Item